JP2002525060A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525060A5 JP2002525060A5 JP2000570334A JP2000570334A JP2002525060A5 JP 2002525060 A5 JP2002525060 A5 JP 2002525060A5 JP 2000570334 A JP2000570334 A JP 2000570334A JP 2000570334 A JP2000570334 A JP 2000570334A JP 2002525060 A5 JP2002525060 A5 JP 2002525060A5
- Authority
- JP
- Japan
- Prior art keywords
- opgl
- polypeptide
- nucleic acid
- animal
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014128 RANK Ligand Human genes 0.000 description 28
- 108010025832 RANK Ligand Proteins 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 13
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- -1 Amino acids Chemical class 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801164 | 1998-09-15 | ||
| US10289698P | 1998-10-02 | 1998-10-02 | |
| US199801164 | 1998-10-02 | ||
| US60/102,896 | 1998-10-02 | ||
| PCT/DK1999/000481 WO2000015807A1 (en) | 1998-09-15 | 1999-09-13 | Method for down-regulating osteoprotegerin ligand activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002525060A JP2002525060A (ja) | 2002-08-13 |
| JP2002525060A5 true JP2002525060A5 (enExample) | 2006-11-02 |
Family
ID=26065320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000570334A Pending JP2002525060A (ja) | 1998-09-15 | 1999-09-13 | オステオプロテゲリンリガンド活性をダウンレギュレートする方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6645500B1 (enExample) |
| EP (1) | EP1114166B1 (enExample) |
| JP (1) | JP2002525060A (enExample) |
| KR (1) | KR100671036B1 (enExample) |
| CN (1) | CN1318105A (enExample) |
| AT (1) | ATE291628T1 (enExample) |
| AU (1) | AU754971B2 (enExample) |
| CA (1) | CA2343654A1 (enExample) |
| CZ (1) | CZ2001789A3 (enExample) |
| DE (1) | DE69924392T2 (enExample) |
| EE (1) | EE200100149A (enExample) |
| ES (1) | ES2239457T3 (enExample) |
| HK (1) | HK1040261A1 (enExample) |
| HR (1) | HRP20010188A2 (enExample) |
| HU (1) | HUP0103578A3 (enExample) |
| ID (1) | ID28386A (enExample) |
| IL (2) | IL141588A0 (enExample) |
| NO (1) | NO20011304L (enExample) |
| NZ (1) | NZ510508A (enExample) |
| PL (1) | PL196790B1 (enExample) |
| PT (1) | PT1114166E (enExample) |
| SK (1) | SK3062001A3 (enExample) |
| TR (1) | TR200100737T2 (enExample) |
| WO (1) | WO2000015807A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9808545A (pt) * | 1997-04-16 | 2000-05-23 | Amgen Inc | ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| IL141588A0 (en) * | 1998-09-15 | 2002-03-10 | M & E Biotech As | Method for down-regulating osteoprotegerin ligand activity |
| GB9908263D0 (en) * | 1999-04-13 | 1999-06-02 | Binding Site The Limited | Eliciting improved immune responses |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| EP1207873B1 (en) * | 1999-07-28 | 2009-11-18 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
| US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
| WO2001023559A1 (en) * | 1999-09-27 | 2001-04-05 | Eli Lilly And Company | Osteoclast differentiation factor regulatory region |
| AUPQ314799A0 (en) * | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
| JP5025871B2 (ja) * | 2000-02-21 | 2012-09-12 | エイチ．リュンドベック エイ／エス | アミロイドの新規なダウン−レギュレート方法 |
| MXPA02007796A (es) * | 2000-02-21 | 2003-12-08 | Pharmexa As | Metodo novedoso para la disminucion de cuerpos amiloides. |
| WO2001062932A1 (en) * | 2000-02-23 | 2001-08-30 | Amgen Inc. | Antagonistic selective binding agents of osteoprotegerin binding protein |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| US20030215450A1 (en) * | 2000-05-26 | 2003-11-20 | Blake Simon M | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| WO2002015846A2 (en) * | 2000-08-21 | 2002-02-28 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| JPWO2002024228A1 (ja) * | 2000-09-21 | 2004-01-29 | 株式会社先端科学技術インキュベーションセンター | 破骨細胞形成を制御する方法 |
| DE60129254T2 (de) | 2000-09-22 | 2008-03-13 | Immunex Corp., Thousand Oaks | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| EP1385532A4 (en) * | 2001-03-22 | 2004-12-15 | Barnes Jewish Hospital | STIMULATION OF THE OSTEOGENESIS WITH RANG-LIGAND FUSION PROTEINS |
| RU2324705C2 (ru) | 2001-04-03 | 2008-05-20 | Сосьете Де Продюи Нестле С.А. | Остеопротегерин, применение его для изготовления фармацевтической композиции (варианты) и получения пищевого продукта (варианты) и корма для животных, пищевой продукт, корм для животных и фармацевтическая композиция для профилактики или лечения расстройств, связанных с костным ремоделированием, и/или иммунных расстройств |
| ES2706902T3 (es) * | 2001-06-26 | 2019-04-01 | Amgen Inc | Anticuerpos para OPGL |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US20030109444A1 (en) * | 2001-10-12 | 2003-06-12 | Jonathan Lam | Bone anti-resorptive compounds |
| JP4336467B2 (ja) * | 2001-10-15 | 2009-09-30 | 株式会社林原生物化学研究所 | 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法 |
| EP1576088A4 (en) | 2002-01-04 | 2006-09-06 | Xencor Inc | DOMINANT NEGATIVE PROTEINS AND METHOD THEREFOR |
| EP1560843A4 (en) * | 2002-01-04 | 2006-09-06 | Xencor Inc | NEW VARIANTS OF RANKL PROTEIN |
| US7381792B2 (en) | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
| US7718776B2 (en) * | 2002-04-05 | 2010-05-18 | Amgen Inc. | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| AU2003297833A1 (en) | 2002-12-10 | 2004-06-30 | Schering-Plough Ltd. | Canine rankl and methods for preparing and using the same |
| RU2006146605A (ru) * | 2004-06-02 | 2008-07-20 | Цитос Биотехнологи Аг (Ch) | Медицинские применения конъюгатов-носителей tnf-пептидов из организма кроме человека |
| US20080107597A1 (en) * | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
| WO2008088594A2 (en) * | 2007-01-12 | 2008-07-24 | Anaptysbio, Inc. | Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species |
| CN101434656B (zh) * | 2007-11-16 | 2011-12-14 | 首都医科大学 | Opg-hsp70融合蛋白的制备方法及用途 |
| JP5866601B2 (ja) * | 2008-06-18 | 2016-02-17 | ザ テキサス エーアンドエム ユニバーシティ システムＴｈｅ Ｔｅｘａｓ Ａ＆Ｍ Ｕｎｉｖｅｒｓｉｔｙ Ｓｙｓｔｅｍ | 医薬組成物の製造方法 |
| WO2011128892A2 (en) * | 2010-04-12 | 2011-10-20 | Protea Vaccine Technologies Ltd. | Modified forms of pneumococcal surface immunogenic protein b (psipb) |
| CN107286245B (zh) * | 2016-04-11 | 2021-10-08 | 北京普纳生物科技有限公司 | Pd-l1和pd-l2重组蛋白及其用途 |
| CN107286244B (zh) * | 2016-04-11 | 2021-10-08 | 北京普纳生物科技有限公司 | 抗免疫检查点pd-l1和pd-l2肿瘤疫苗 |
| CN108498786A (zh) * | 2018-02-13 | 2018-09-07 | 南昌大学第二附属医院 | 载骨保护素的缓释纳米粒及其制备方法和应用 |
| KR102154637B1 (ko) * | 2018-11-12 | 2020-09-10 | 조선대학교산학협력단 | Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물 |
| US20250304708A1 (en) * | 2022-09-07 | 2025-10-02 | The Regents Of The University Of California | Treatment of cancer by blockade of osteoprotegerin |
| KR20250118303A (ko) * | 2024-01-29 | 2025-08-06 | 주식회사 아크젠바이오사이온스 | Rankl의 돌연변이체 및 이를 포함하는 백신 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1237764B (it) * | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| DE4496393T1 (de) | 1993-08-27 | 1996-11-21 | Dow Chemical Co | Verfahren zur Trennung von Enantiomeren |
| EP0755444A4 (en) * | 1994-04-01 | 1998-01-14 | Univ Utah | MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA |
| US6340459B1 (en) * | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| DE69738811D1 (de) * | 1996-12-13 | 2008-08-14 | Schering Corp | Oberflächenantigene aus Säugern |
| WO1998028424A2 (en) * | 1996-12-23 | 1998-07-02 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| BR9808545A (pt) * | 1997-04-16 | 2000-05-23 | Amgen Inc | ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento |
| IL141588A0 (en) * | 1998-09-15 | 2002-03-10 | M & E Biotech As | Method for down-regulating osteoprotegerin ligand activity |
-
1999
- 1999-09-13 IL IL14158899A patent/IL141588A0/xx unknown
- 1999-09-13 PT PT99942778T patent/PT1114166E/pt unknown
- 1999-09-13 AU AU56173/99A patent/AU754971B2/en not_active Ceased
- 1999-09-13 NZ NZ510508A patent/NZ510508A/en unknown
- 1999-09-13 CA CA002343654A patent/CA2343654A1/en not_active Abandoned
- 1999-09-13 HK HK02100128.3A patent/HK1040261A1/zh unknown
- 1999-09-13 AT AT99942778T patent/ATE291628T1/de not_active IP Right Cessation
- 1999-09-13 ES ES99942778T patent/ES2239457T3/es not_active Expired - Lifetime
- 1999-09-13 TR TR2001/00737T patent/TR200100737T2/xx unknown
- 1999-09-13 JP JP2000570334A patent/JP2002525060A/ja active Pending
- 1999-09-13 EP EP99942778A patent/EP1114166B1/en not_active Expired - Lifetime
- 1999-09-13 CZ CZ2001789A patent/CZ2001789A3/cs unknown
- 1999-09-13 EE EEP200100149A patent/EE200100149A/xx unknown
- 1999-09-13 PL PL346698A patent/PL196790B1/pl not_active IP Right Cessation
- 1999-09-13 KR KR1020017003379A patent/KR100671036B1/ko not_active Expired - Fee Related
- 1999-09-13 SK SK306-2001A patent/SK3062001A3/sk not_active Application Discontinuation
- 1999-09-13 WO PCT/DK1999/000481 patent/WO2000015807A1/en not_active Ceased
- 1999-09-13 HU HU0103578A patent/HUP0103578A3/hu unknown
- 1999-09-13 CN CN99810872A patent/CN1318105A/zh active Pending
- 1999-09-13 DE DE69924392T patent/DE69924392T2/de not_active Expired - Fee Related
- 1999-09-13 HR HR20010188A patent/HRP20010188A2/hr not_active Application Discontinuation
- 1999-09-13 ID IDW20010822A patent/ID28386A/id unknown
- 1999-09-15 US US09/396,937 patent/US6645500B1/en not_active Expired - Fee Related
-
2001
- 2001-02-22 IL IL141588A patent/IL141588A/en not_active IP Right Cessation
- 2001-03-14 NO NO20011304A patent/NO20011304L/no not_active Application Discontinuation
-
2003
- 2003-09-17 US US10/664,801 patent/US20040115199A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002525060A5 (enExample) | ||
| JP4087898B2 (ja) | 免疫原性に乏しい抗原と合成ペプチド担体との結合体およびそれらからなるワクチン | |
| CN108778322B (zh) | 铜绿假单胞菌pcrv连接的抗原疫苗 | |
| KR860700090A (ko) | 어드헤신(Adhesin)항원 | |
| JP3267333B2 (ja) | 融合タンパク質 | |
| Dale et al. | Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein. | |
| CA2457140A1 (en) | Beta-amyloid-analogue - t-cell epitope vaccine | |
| EP0429816A1 (en) | Vaccine composition with non-immunosuppresive T-cell epitope component | |
| HRP20010900A2 (en) | Method for down-regulating gdf-8 activity | |
| JPH04502402A (ja) | 組み換えフラジエリンのワクチン | |
| AU707083B2 (en) | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes | |
| ES2236718T3 (es) | Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna. | |
| Roberts et al. | Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P. 69 and FHA | |
| EP0638092B1 (en) | Synthetic peptide vaccines for dental caries | |
| JP2006503017A5 (enExample) | ||
| US5824309A (en) | Recombinant gas vesicles and uses thereof | |
| AU630093B2 (en) | Synthetic peptides from streptococcal m protein and vaccines prepared therefrom | |
| WO1997020854A9 (en) | Recombinant gas vesicles and uses thereof | |
| HK1006674B (en) | Synthetic peptides from streptococcal m protein and vaccines prepared therefrom | |
| ZA200302628B (en) | Method for down-regulating IgE. | |
| BR102020013216A2 (pt) | Processo de obtenção de vesículas apresentadoras de antígenos (vaa) que possibilita o acoplamento de um ou mais antígenos | |
| JP2004529881A (ja) | 合成ワクチン剤 | |
| Kozuka et al. | Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity | |
| AU2003285280A1 (en) | Targeting single epitopes | |
| WO2004024183B1 (en) | Immunization against autologous ghrelin |